FDA
-
-
-
-
-
-
-
Vertex Announces CASGEVY® Reimbursement Agreement for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia in Germany
-
-
-
-
-
-
-
Vertex reports positive phase 3 results for IgA nephropathy drug
-
-
-
-
-
-
-
Vertex reports drug pipeline progress ahead of investor meetings
-
-
-
-
-
-
-
Vertex Reports Third Quarter 2025 Financial Results
-
-
-
-
-
-
-
Vertex receives FDA breakthrough therapy designation for kidney drug
-
-
-
-
-
-
-
Vertex (VRTX) PT Raised to $471 at Bernstein SocGen Group
-
-
-
-
-
-
-
FDA Cell and Gene Therapy Roundtable 'bullish for the space' - Stifel
-
323,104 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

